A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis (NCT07223697)

🧪 Interventions in This Study

• Afimkibart (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (28 Sites)

Showing the first 25 of 28 sites.

• UCLA Division of Dermatology — Los Angeles, California
• Olympian Clinical Research — Tampa, Florida
• Hamilton Research, LLC — Alpharetta, Georgia
• Revival Research Institute, LLC — Troy, Michigan
• Best Skin Research LLC — Camp Hill, Pennsylvania
• Centro de Estudos em Terapias Inovadoras ? CETI — Curitiba, Paraná
• Irmandade Da Santa Casa de Misericordia de Porto Alegre — Porto Alegre, Rio Grande do Sul
• Hospital de Clnicas de Porto Alegre — Porto Alegre, Rio Grande do Sul
• UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu — Botucatu, São Paulo
• Centro de Pesquisa São Lucas — Campinas, São Paulo
• HMCG - Hospital e Maternidade Dr. Christovo da Gama — Santo Andr, São Paulo
• Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS — Sao Jose Rio Preto, São Paulo
• Instituto Brasil de Pesquisa Clínica-IBPCLIN S/A — Rio de Janeiro,
• DermEffects — London, Ontario
• Lynderm Research Inc — Markham, Ontario
• DermEdge — Mississauga, Ontario
• Ryan Clinical Research Inc — Newmarket, Ontario
• Fachklinik Bad Bentheim — Bad Bentheim, Lower Saxony
• Dermatologikum Hamburg Gemeinschaftspraxis GbR — Hamburg,
• Azienda Ospedaliero Universitaria delle Marche — Ancona, The Marches
• Centrum Medyczne Pratia Katowice I — Katowice, Silesian Voivodeship
• Centrum Medyczne Pratia Gdynia — Gdynia,
• Specjalistyczny Gabinet Dermatologiczny dr n. med. Pawel Brzewski — Krakow,
• Centrum Nowoczesnych Terapii "Dobry Lekarz" — Krakow,
• Uniwersytecki Szpital Kliniczny im.Fryderyka Chopina w Rzeszowie — Rzeszów,

📞 Contact the Study Coordinator

Phone: (888) 662-6728

Email: global-roche-genentech-trials@gene.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Atopic Dermatitis

• A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden — Birmingham, Alabama
• ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis — Phoenix, Arizona
• A Study of Barzolvolimab in Patients With Atopic Dermatitis — Birmingham, Alabama
• Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis — Chicago, Illinois
• A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis — Birmingham, Alabama
• A Study Evaluating APG777 in Atopic Dermatitis — Fountain Valley, California

Explore by condition: All Atopic Dermatitis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.